SERADYN, INC. – Trademark Portfolio
Entity Type: 03
SERADYN, INC. holds 26 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 13 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include QMS, OPTIBIND, OPTILINK, SERA-MAG, and COLOR SLIDE. The owner is based in INDIANAPOLIS, IN.
1200 MADISON AVENUE
INDIANAPOLIS, IN 46206
Showing of trademarks Trademarks
Trademark Classifications
SERADYN, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does SERADYN, INC. have?
SERADYN, INC. has 26 U.S. trademarks filed with the USPTO. Of these, 5 registered, 8 abandoned, 13 cancelled.
What trademark classes does SERADYN, INC. file in?
SERADYN, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SERADYN, INC.'s most well-known trademarks?
SERADYN, INC.'s registered trademark portfolio includes well-known marks such as QMS, OPTIBIND, OPTILINK, SERA-MAG, and COLOR SLIDE. These are among 5 currently registered trademarks in the portfolio.
What is SERADYN, INC.'s trademark registration success rate?
SERADYN, INC. has a 19% trademark registration rate, with 5 out of 26 resolved applications resulting in successful registration. Currently, 0 applications are pending review.